Kornimate/medical-research-clean huggingface dataset:
the new skin stretching device for treatment of limb tension wounds

Conditions: Trauma; Fractures, Open; Wounds and Injuries; Skin Expander

Summary: a randomized controlled trial is performed to evaluate the effectiveness and safety of the skin stretching device (ssd) on limb tension incision closure by comparing whether the differences in wounds area, wounds closure time and scar assessment between the ssd and the skin grafting are statistically significant.

design: this study is a multicenter and randomized control study with the participation of 15 major national or regional central hospitals. and the whole sample size is set to be 100 patients. patients who have been screened by inclusion and exclusion criteria will be randomly (non-transparent envelope) assigned to skin stretching group (ss group) or skin grafting group (sg group). patients of both group will undergo surgical debridement for the same principle, while the skin stretching device is used for the patients of ss group for incision closure and the skin grafting is used for the patients of sg group for incision closure. outcome evaluation: wound and scar evaluation during surgery, three and six months after surgery will include the following parameters: * surface area; * vancouver scar scale (vss) * vascularization and pigmentation; * dermal architecture. after 3 and 6 months patients will undergo a biopsy of the scar under local anesthesia. the experimental group, treated with the ssd will undergo one extra biopsy of the formerly stretched skin. safety evaluation: during the trial, adverse events are observed and evaluated. adverse reactions to clinical manifestations are followed and recorded till the symptoms disappear. the subject with serious adverse events shall withdraw from the study and be treated accordingly.

Eligibility criteria:
inclusion criteria: 1. age≥18 years old 2. tension incision that cannot be directly closed due to limb trauma or surgical debridement 3. incision that cannot be directly closed after the incision decompression for fascia compartment syndrome and ischemia and reperfusion injury 4. both sides of the incision skin suitable for skin stretching exclusion criteria: 1. age \<18 years old 2. skin disease 3. keloid history 4. local or systemic use of hormones 5. systemic diseases: for example, diabetes, immunodeficiency disease, vascular disease and etc. 6. other poor general state to result in inability for trial; 7. mental illness.

Keywords: tension wound skin stretching device skin grafting
biodex training in hemodialysis females with osteopenia

Conditions: Hemolysis

Summary: imbalance is a common problem in hemodialysis patients with osteopneia, biodex training is a good device that treat imbalance

58 women with osteopenia problem and dialysis will be divided to trained women group with a number of 29 women receiving 3-time biodex training per week, every time will be 10 minutes for 12 weeks or nontrained women group that will act as a control group (n = 29 women)

Eligibility criteria:
inclusion criteria: * osteopneia women * hemodialysis women exclusion criteria: * pregnancy * autoimmune disorders * lower limb orthopedic problems * psychological manifestaion
efficacy and safety of single, low-dose dexamethasone in patients after total knee arthroplasty

Conditions: Osteoarthritis, Knee

Summary: this study was conducted to determine the efficacy of an additional preemptive, single, low-dose dexamethasone in terms of incidence and severity of postoperative nausea/vomiting (ponv), pain level, and the safety in terms of wound complications in patients managed with our antiemetic protocol based on ramosetron following tka.

postoperative pain and emesis can cause postoperative systemic complications and delay recovery and rehabilitation in patients following total knee arthroplasty (tka). furthermore, patients who suffered from severe postoperative pain and emesis tend to be dissatisfied with their surgical treatments. although contemporary protocols to control perioperative pain and emesis after tka have been reported to substantially reduce postoperative pain and emesis compared with traditional measures, pain and emesis after tka remain to be a challenging issue for patients and health care providers. in our previous study, the use of ramosetron was found to reduce postoperative emetic events, but the antiemetic effects by ramosetron were incomplete. in search of a further antiemetic measure, we identified the use of dexamethasone as the additional measure fortifying our antiemetic protocol using ramosetron.

Eligibility criteria:
inclusion criteria: * diagnosis of primary osteoarthritis, knee * scheduled for elective total knee arthroplasty * signed written informed consent exclusion criteria: * refusing participate * contraindication to regional anesthesia * severe impairment of bowel motility * administration of other antiemetic drug within 24hours before surgery * systemic steroid within 24hours before surgery * history of cardiovascular \& respiratory disease * renal \& hepatic failure

Keywords: postoperative nausea and vomiting postoperative pain
feasibility of mindbeagle in disorders of consciousness or locked-in syndrome

Conditions: Consciousness Disorders; Locked-In Syndrome

Summary: the primary aims of this study are: 1. to determine the feasibility of deploying mindbeagle, a portable, bedside eeg-based system, in the intensive care unit in patients with disorders of consciousness (doc) or locked-in syndrome (lis); 2. to determine if mindbeagle neurophysiologic markers of cognitive function correlate with bedside behavioral assessments of consciousness; 3. to determine if mindbeagle neurophysiologic markers of cognitive function correlate with functional mri (fmri) and electroencephalography (eeg) biomarkers of consciousness; 4. to determine if mindbeagle can serve as an assistive communication device for people with lis.

1. to determine the feasibility of deploying mindbeagle, a portable, bedside eeg-based system, in the neurosciences intensive care unit in patients with doc or lis; 2. to determine if mindbeagle neurophysiologic markers of cognitive function correlate with bedside behavioral assessments of consciousness; 3. to determine if mindbeagle can serve as an assistive communication device for people with lis.

Eligibility criteria:
inclusion criteria: * age\>18 * diagnosis of coma * vegetative state * minimally conscious state * confusional state * locked-in state exclusion criteria: • history of developmental, neurologic, or major psychiatric disorder resulting in functional disability
cohort study of auricular acupressure for postoperative pain after hemorrhoidectiomy

Conditions: Postoperative Pain After Hemorrhoidectomy

Summary: auricular pressure is effective for postoperative analgesia after hemorrhoidectomy, but the evidence is not sufficient.

this is a cohort study to study the analgesic effect of auricular pressure pill on persistent pain after hemorrhoidectiomy. baseline pain intensity scores (vas\>3) of the subjects will be collected 3 hours after the operation of the patients. by doctors' recommend interventions and the patients' preference, eligible subjects were naturally divided into the following queues: intravenous patient-controlled analgesia(iv-pca),intravenous dezocine(iv-dezocine),intravenous patient-controlled analgesia+auricular acupressure(iv-pca+aa),intravenous dezocine+auricular acupressure(iv-dezocine+aa). the treatment will last 5-7 days. participants will receive auricular pressure once two days, and receive vas, concomitant medication, ponv intensity scale and peripheral edema were recorded daily, and after the operation 3 hours, 3 days and 7 days the patients will receive anxiety and depression scale(had) , and vas data will be collected by telephone at 3 and 6 months after the operation. the main indicators will be analyzed by vas score and generalized linear model, with vas results as the dependent variable, grouping as the random factor, surgical method, mixed hemorrhoid classification as fixed effects factor, and age, course of disease, baseline vas scores and vas follow-up time point as the covariables to analysis vas score improved relations between various factors. analgesic usage, ease pain evaluation method and using the same scale and had glm model analysis.the secondary indicator analgesic usage rate will be analyzed using logistic regression analysis. fixed effects and covariate factors set with the glm model. the purpose of this study was to seek high quality evidence-based medical evidence for intervention of auricular pressure pills on postoperative pain of hemorrhoidectomy.

Eligibility criteria:
inclusion criteria: 1. meet the diagnostic criteria of grade ii-iv mixed hemorrhoids and meet the operation conditions; 2. age 18\~65; 3. external stripping and internal ligation of mixed hemorrhoids, general anesthesia or lumbar shu point anesthesia; 4. vas score ≥3 points; 5. sign informed consent. exclusion criteria: * combined cognitive impairment could not complete the efficacy evaluation; * with other gastrointestinal conditions found during operation; * with severe cardiovascular, hepatic, or renal diseases; * with opioid addiction

Keywords: hemorrhoidectiomy postoperative pain auricular pressure
observational, retrospective, multicenter, nonprofit study on the prevalence of renal involvement in pediatric patients with tuberous sclerosis

Conditions: Tuberous Sclerosis Complex (TSC)

Summary: observational, retrospective, multicenter, nonprofit study on the prevalence of renal involvement in pediatric patients with tuberous sclerosis.

tuberous sclerosis (tsc) is an autosomal dominant transmission neurocutaneous syndrome caused by mutations in the tsc1 (9q34) and tsc2 (16p13.3) genes. renal involvement in tuberous sclerosis is frequent and consists of the presence of angiomyolipomas, cysts, increased risk of renal carcinoma (predominantly clear cell renal cell carcinoma), and proteinuria in the absence of angiomyolipomas or cysts, which may evolve into chronic kidney disease. renal involvement in tuberous sclerosis is often asymptomatic, and in most cases the finding of angiomyolipomas, cysts, or changes in renal function is an occasional finding on examinations performed during follow-up. angiomyolipomas are the most frequent form of renal involvement in tuberous sclerosis and, when symptomatic, cause potentially fatal hemorrhages (intratumoral or retroperitoneal), anemia, hypertension, hematuria, and renal failure due to subversion of the renal parenchyma. the renal picture of tsc (hemorrhage, end-stage renal disease, and metastasis to renal carcinoma) is the second leading cause of death in pediatric tsc patients, after neurological, and the first in the adult population. data regarding renal involvement in the pediatric population with tsc are scarce in the literature. this study aims to assess the prevalence of renal involvement in pediatric tsc patients. more in detail, the primary aim is to assess the prevalence of angiomyolipomas and renal cysts in pediatric tsc patients. the secondary aims are to evaluate the correlation between genetic alteration and the presence of angiomyolipomas and renal cysts in tsc patients; to evaluate the renal outcome in terms of renal function and blood pressure in pediatric tsc patients with renal involvement; to evaluate the volume change of angiomyolipomas in pediatric patients with tsc on everolimus therapy prescribed for neurological complications.

Eligibility criteria:
inclusion criteria: * patients of either sex under the age of 17 years at the time of last observation (06/30/2021); * patients clinically evaluated in an outpatient or inpatient setting during 01/01/2018- 30/06/2021 with a diagnosis of tsc; * informed consent signed by parent or legal guardian. exclusion criteria: * patients older than 18 years of age; * patients with other phacomatoses.

Keywords: tuberous sclerosis complex nephropathy children
clinical value of homeopathic prophylaxis of recurrent urinary tract infections in persons with spinal cord injury

Conditions: Symptomatic Urinary Tract Infection; Spinal Cord Injury

Summary: recurrent symptomatic urinary tracts infections (uti) in persons with spinal cord injury are a frequent problem, leading to significant morbidity and to a decreased quality of life. * until today, there is no effective prophylaxis for uti for patients with spinal cord injury. * homeopathy has been shown to be an effective treatment option in several chronic diseases * study hypothesis: the addition of homeopathic assessment and treatment to a standard prevention strategy for recurrent uti will significantly reduce the number of symptomatic uti per year in this group of patients compared to standard prevention alone


Eligibility criteria:
inclusion criteria: * neurogenic bladder dysfunction treated by intermittent catheterization * recurrent (\>3/year) symptomatic urinary tract infections exclusion criteria: * inability to speak german * already under homeopathic treatment

Keywords: urinary tract infection spinal cord injury homeopathy prevention
er:yag laser and air polishing application in periodontal treatment

Conditions: Periodontitis

Summary: periodontitis (gum disease) is an infection of the gums that can lead to tooth loss. in recent years, many types of dental lasers or other devices have been used for the non-surgical treatment of periodontal diseases. however, it remains unclear whether the combined application of laser and air polishing is effective as an adjuvant treatment for periodontitis. the purpose of this study is to compare the use of combined application of er:yag laser and sub-gingival air polishing powder, with the treatment of er:yag laser only, in periodontal diseases treatment in a chinese population.

the study will use a split-mouth design, two quadrants (one quadrant from each jaw) were randomly allocated to either the test or control group. the quadrants in the test group received er:yag laser (erl) plus sub-gingival air polishing treatment, while the quadrants in the control group received erl only. clinical periodontal examinations were evaluated at baseline, 3 months, 6 months, 1 year, and 2 years.

Eligibility criteria:
inclusion criteria: * 1) aged 35-65 years old, in good systemic healthy; * 2) clinically diagnosed with generalized stage ⅱ or stage ⅲ periodontitis; * 3) a minimum of 20 teeth exclusion criteria: * 1) pregnancy or recent pregnancy plans; * 2) had received periodontal treatment within the previous 6 months; * 3) taken antibiotics within the previous 3 months; * 4) had diabetes; * 5) obvious malocclusion, history of orthodontic treatment, or a habit of mouth breathing.

Keywords: generalized, stage ⅱ or stage ⅲ
the different analgesic potency of volatile anesthetics at equi-mac

Conditions: Orthopedic Disorders

Summary: the aim of this clinical trial is to evaluate the difference of analgesic potency of sevoflurane and desflurane at equi-minimum alveolar concentration using a surgical pleth index.

volatile anesthetics vary in their relative hypnotic potencies. recent studies demonstrated that equi-minimum alveolar concentration of various volatile anesthetics produced different eeg-derived indices such as bispectral index. however, there was no controlled study that demonstrates the difference of analgesic potency. the aim of this clinical trial is to evaluate the difference of analgesic potency of sevoflurane and desflurane at equi-minimum alveolar concentration using a surgical pleth index.

Eligibility criteria:
inclusion criteria: * patients undergoing arthroscopic shoulder surgery * patients with american society of anesthesiologist physical status i, ii * patients aged 19-65 years * patients obtaining written informed consent exclusion criteria: * patients with a history of any psychiatric or neurological disease * patients who had received any medication affecting the central nervous system * patients who had received medication affecting the sympathetic or parasympathetic nervous systems * patients who have not received interscalene approach brachial plexus block (refusal or failure) * pregnant women
conditioning regimen in elderly aml patients receiving haplo-hsct.

Conditions: AML; Elderly

Summary: elderly aml patients receiving conventional chemotherapy have poor prognosis. allo-hsct offers better long-term survival than chemotherapy, while high trm limits its use. current research focuses more on improving conditioning regimens to reduce trm. studies suggest bu/flu/cy/atg are safer and more effective for elderly aml haplo-hsct, lowering trm. however, prospective randomized trials are lacking. this study aims to compare bu/flu/cy/atg vs. bu/cy/atg to determine if trm can be reduced in elderly aml undergoing haplo-hsct.

the prognosis of elderly patients with acute myeloid leukemia (aml) undergoing conventional chemotherapy is poor. compared with chemotherapy, allogeneic hematopoietic stem cell transplantation (allo-hsct) can improve long-term survival in elderly patients. however, the high transplantion-related mortality (trm) limited its application. currently, the top priority in transplantation for elderly aml patients is to reduce trm through methods such as optimizing conditioning regimens, reducing graft-versus-host disease (gvhd), and preventing infections. present research primarily focuses on optimizing conditioning regimens. both domestic and international studies, as well as our team's preliminary research, suggest that replacing cyclophosphamide (cy) with fludarabine (flu) can reduce toxicity. earlier prospective single-arm clinical study in our team confirmed that the bu/flu/cy/atg regimen is a safe and effective conditioning protocol for haploidentical hematopoietic stem cell transplantation (haplo-hsct) in elderly aml patients. this study aims to use a prospective randomized controlled trial to verify whether the bu/flu/cy/atg conditioning regimen can reduce trm compared with the bu/cy/atg regimen in elderly aml patients undergoing haplo-hsct.

Eligibility criteria:
inclusion criteria: - (a)diagnosed with aml in first complete remission (cr1). (b)age ≥55 years. (c)availability of an haploidentical donor, first transplant, no matched sibling or unrelated donor. (d)willingness to provide written informed consent. exclusion criteria: * (a) uncontrolled active infection. (b) secondary aml. (c)refusal to provide informed consent.

Keywords: haplo-hsct elderly aml ric
the navigator project

Conditions: HIV

Summary: each year, there are over 600 unduplicated hiv-infected persons incarcerated in the san francisco jail. two thirds of those released with hiv-focused discharge planning are reincarcerated within one year. more than half of hiv-infected jail inmates are diagnosed with mental health conditions severe enough to require medication and a similar proportion report substance use disorders at the time of detention. while some community-based services exist, there remains a critical need to improve linkages to care and adherence to care plans for hiv-infected adults as they move between community and jail. the navigator project is a five-year randomized study that will test the effectiveness of an intensive enhanced case management intervention to reduce sex and drug-related hiv transmission risk; increase hiv medication adherence; reduce drug dependence; and reduce reincarceration.


Eligibility criteria:
inclusion criteria: * detention in the san francisco jail system * confirmed hiv infection * lifetime history of ever having met standardized criteria for drug or alcohol addiction * likely release back into san francisco without transfer to another facility * agreement to work with forensic aids project to plan post-release care * able and willing to provide informed consent * not scheduled for release within 36 hours exclusion criteria: * undocumented hiv status * inability to speak english or spanish * unable or unwilling to provide informed consent * not under routine level of jail security

Keywords: hiv detention substance abuse
compassionate use of beraprost sodium 314d modified release for patients with pulmonary arterial hypertension (pah)

Conditions: Pulmonary Arterial Hypertension

Summary: the purpose of this study is to see if lung llc's new experimental formulation of the medicine beraprost sodium, called beraprost sodium 314d modified release (bps-314d-mr), can improve the symptoms of pulmonary arterial hypertension (pah) in patients. an experimental drug is one that has not been approved by the u.s. food and drug administration for use in the general public. this research study is for patients who have pulmonary arterial hypertension (pah) and have just completed taking part in an earlier research study and received an older experimental formulation of beraprost sodium, called beraprost sodium modified release (bps-mr). that earlier study was being done to see if bps-mr could improve their pah. patients may also be taking tyvaso (treprostinil), tracleer (bosentan), letairis (ambrisentan), adcirca (tadalafil) and/or viagra or revatio (sildenafil) to treat their pah. the diagnosis of pah means that the blood pressure in their lungs is higher than normal. the increased blood pressure in the lungs places a strain on the heart. the strain causes the heart to pump less blood into the lungs, causing shortness of breath and tiredness. the strain on the heart weakens the heart muscle making it less able to pump blood, a condition called heart failure. as heart failure develops, swelling in the feet and abdomen may occur.

according to lung llc, and from my review of summary results contained within the most recent version of the bps-314d-mr investigators' brochure i concur, bps-314d- mr has been shown to have a similar safety and pharmacokinetic profile in healthy volunteers to bps-mr. it is also my understanding that at an end of phase ii meeting in april of this year, fda acknowledged lung llc's intention to continue the development of bps-314d-mr by conducting a phase iii pivotal study in pah patients. this study, bps-314d-mr-pah-302 was subsequently initiated this past june. in my opinion, and based upon the similarities of the two formulations, it is in the best interest of our patients to transition their treatment to bps-314d-mr. lung llc has agreed to supply bps-314d-mr for the patients.

Eligibility criteria:
inclusion criteria: * prior participation in beraprost-mr study at harbor-ucla exclusion criteria: * no prior participation in beraprost study at harbor-ucla

Keywords: pulmonary arterial hypertension prostacyclin oral